Cancer Immunotherapy Drugs Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators), Indication (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-user - Global Forecast 2024-2030

Cancer Immunotherapy Drugs Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators), Indication (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-user - Global Forecast 2024-2030


The Cancer Immunotherapy Drugs Market size was estimated at USD 215.29 billion in 2023 and expected to reach USD 243.31 billion in 2024, at a CAGR 13.10% to reach USD 509.93 billion by 2030.

Global Cancer Immunotherapy Drugs Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Immunotherapy Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Immunotherapy Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Immunotherapy Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, CARsgen Therapeutics, Celldex Therapeutics, Inc., ElevateBio, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Ikena Oncology, Incyte Corporation, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, OSE Immunotherapeutics SA, Pfizer Inc., QIAGEN N.V., Sanofi SA, Seattle Genetics Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage



This research report categorizes the Cancer Immunotherapy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
Monoclonal Antibodies
Indication
Breast Cancer
Colorectal Cancer
Head & Neck Cancer
Lung Cancer
Melanoma
Prostate Cancer
End-user
Ambulatory Surgical Center
Hospitals & Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer Immunotherapy Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Immunotherapy Drugs Market?
3. What are the technology trends and regulatory frameworks in the Cancer Immunotherapy Drugs Market?
4. What is the market share of the leading vendors in the Cancer Immunotherapy Drugs Market?
5. Which modes and strategic moves are suitable for entering the Cancer Immunotherapy Drugs Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Immunotherapy Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in prevalence of cancer across the world
5.1.1.2. Growing adoption of immunotherapy over other treatments
5.1.1.3. Developments of bioinformatics tools and resources for cancer immunotherapy study
5.1.2. Restraints
5.1.2.1. High cost of therapy and unpredictable effectiveness of immuno-oncology agents
5.1.3. Opportunities
5.1.3.1. Recent developments in immunotherapy technologies
5.1.3.2. Significant investment and funding for immunotherapy research
5.1.4. Challenges
5.1.4.1. Possibilities of adverse effects of the available therapies
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cancer Immunotherapy Drugs Market, by Type
6.1. Introduction
6.2. Cancer Vaccines
6.3. Checkpoint Inhibitors
6.4. Immunomodulators
6.5. Monoclonal Antibodies
7. Cancer Immunotherapy Drugs Market, by Indication
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Head & Neck Cancer
7.5. Lung Cancer
7.6. Melanoma
7.7. Prostate Cancer
8. Cancer Immunotherapy Drugs Market, by End-user
8.1. Introduction
8.2. Ambulatory Surgical Center
8.3. Hospitals & Clinics
9. Americas Cancer Immunotherapy Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Immunotherapy Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Immunotherapy Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie, Inc.
13.1.2. Amgen Inc.
13.1.3. Astellas Pharma Inc.
13.1.4. AstraZeneca PLC
13.1.5. Bayer AG
13.1.6. Boehringer Ingelheim International GmbH
13.1.7. Bristol Myers Squibb Company
13.1.8. CARsgen Therapeutics
13.1.9. Celldex Therapeutics, Inc.
13.1.10. ElevateBio
13.1.11. ELI Lilly and Company
13.1.12. F. Hoffmann-La Roche Ltd
13.1.13. Gilead Sciences, Inc.
13.1.14. GlaxoSmithKline PLC
13.1.15. Ikena Oncology
13.1.16. Incyte Corporation
13.1.17. Johnson & Johnson Services, Inc.
13.1.18. Merck & Co., Inc.
13.1.19. Novartis AG
13.1.20. OSE Immunotherapeutics SA
13.1.21. Pfizer Inc.
13.1.22. QIAGEN N.V.
13.1.23. Sanofi SA
13.1.24. Seattle Genetics Inc.
13.1.25. Takeda Pharmaceutical Company Limited
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. CANCER IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER IMMUNOTHERAPY DRUGS MARKET DYNAMICS
FIGURE 7. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CANCER IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CANCER IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings